Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results

Benzinga Earnings

08/04

Inspire Medical Systems Inc (NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.

Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.

Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.

“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.

Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.

These analysts made changes to their price targets on Inspire Medical following earnings announcement.

Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.
Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.

Considering buying INSP stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2656284555"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656284555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656284555?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656284555","market":"us","top_or_hot":-1,"title":"Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> Inc </strong>(NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.</p>\n<p>Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.</p>\n<p>Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.</p>\n<p>“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.</p>\n<p>Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Inspire Medical following earnings announcement.</p>\n<ul>\n<li>Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.</li>\n<li>Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.</li>\n</ul>\n<p><strong>Considering buying INSP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"310\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-300x91.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-768x233.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2026-08-04 20:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> Inc </strong>(NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.</p>\n<p>Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.</p>\n<p>Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.</p>\n<p>“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.</p>\n<p>Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Inspire Medical following earnings announcement.</p>\n<ul>\n<li>Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.</li>\n<li>Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.</li>\n</ul>\n<p><strong>Considering buying INSP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"310\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-300x91.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-768x233.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/60903644/inspire-medical-systems-analysts-raise-their-forecasts-following-strong-q2-results","article_id":"2656284555","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656284555","pubTimestamp":1785845680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"INSPI beats expectations, raises FY26 guidance. Analysts raise price targets to $59 &amp; $60. Stock jumps 14.6% in pre-market trading. #INSP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","INSP":"Inspire Medical Systems","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4167":"医疗保健技术"},"translate_title":"Inspire Medical Systems 分析师在第二季度业绩强劲后上调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":1.5},"content_text":"Inspire Medical Systems Inc (NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.\nInspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.\nInspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.\n「Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,」 said Tim Herbert, Chairman and CEO of Inspire Medical Systems.\nInspire Medical shares jumped 14.6% to $59.85 in pre-market trading.\nThese analysts made changes to their price targets on Inspire Medical following earnings announcement.\n\nBaird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.\nPiper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.\n\nConsidering buying INSP stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}